SCHEMBL3775946

SCHEMBL3775946

C=Cc1cnc(Cl)cc1Nc1ccccc1C(=O)NC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 3/20 0.51
MAPK10 P53779 3/20 0.49
MAPK8 P45983 2/20 0.49
MAPK3 P27361 2/20 0.47
MAPK1 P28482 1/20 0.47
TYK2 P29597 5/20 0.45
JAK2 O60674 4/20 0.45
JAK1 P23458 4/20 0.45
CDK7 P50613 1/20 0.44
CDK9 P50750 1/20 0.44
MET P08581 1/20 0.43
ALK Q9UM73 1/20 0.43
MAPK9 P45984 2/20 0.42
PDE4D Q08499 1/20 0.42
PTK2 Q05397 3/20 0.42
POLB P06746 1/20 0.42
INSR P06213 1/20 0.42
IGF1R P08069 1/20 0.42
PTK2B Q14289 1/20 0.42
PKMYT1 Q99640 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777593 0.85 MAPK10 (0.65) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL690590 0.85 MAPK10 (0.65) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL12887553 0.84 MAPK10 (0.52) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL691209 0.83 ULK1 (0.51) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL691337 0.82 MAPK10 (0.51) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL1558027 0.82 MAPK10 (0.51) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL13060634 0.82 MAPK10 (0.51) ULK1MAPK10MAPK8MAPK3MAPK1
Hydrochloric Acid SCHEMBL3405374 0.81 MAPK10 (0.50) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL18559472 0.80 MAPK10 (0.48) ULK1MAPK10MAPK8MAPK3MAPK1
SCHEMBL30692349 0.80 MAPK10 (0.64) MAPK10MAPK8MAPK9PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
WO-2009105498-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK PTK2, JAK2, SRC ULK1 3788/4885MAPK10 386/4885MAPK8 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.